title: Haemodynamic and renal effects of intravenous enalaprilat during coronary artery bypass graft surgery in patients with ischaemic heart dysfunction.
abstract: Renal dysfunction occurring after open heart surgery is multifactorial in origin but activation of the renin-angiotensin system may have a prominent role. Fourteen patients with ischaemic heart dysfunction scheduled for elective coronary artery bypass graft (CABG) surgery were allocated to a treatment group [enalaprilat for 2 days; ACEI (angiotensin-converting enzyme inhibitor) group, n=7] or a control group (n=7). The cardiac index was significantly higher in ACEI-treated patients than in the controls before and after cardiopulmonary bypass (CPB) (P<0.05) and on postoperative day 2 (P<0.05). The systemic vascular resistance was significantly lower in the ACEI-treated patients than in the controls before and after CPB (P<0.05). Renal plasma flow, measured as [131I]orthoiodohippuran clearance (ClH), was higher in the ACEI group than in the control group before CPB, as was endogenous creatinine clearance after CPB (P<0.05). On post-operative day 7, ClH was significantly higher in the ACEI group than in the control group (P<0.05). Plasma renin activity and vasopressin concentration increased in both groups during CPB (P<0.05). The study demonstrates that administration of an i.v. ACEI, enalaprilat, improves cardiac output during CABG surgery in patients with ischaemic heart dysfunction. Moreover, renal perfusion was better maintained during surgery, and this effect was sustained up to post-operative day 7.
authors.affiliation: Department of Anaesthesiology and Intensive Care, Hopital Arnaud de Villeneuve, Giraud, Montpellier, France.
authors.forename: F
authors.initials: F
authors.lastname: Ryckwaert
authors.forename: P
authors.initials: P
authors.lastname: Colson
authors.forename: J
authors.initials: J
authors.lastname: Ribstein
authors.forename: G
authors.initials: G
authors.lastname: Boccara
authors.forename: G
authors.initials: G
authors.lastname: Guillon
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001127:Arginine Vasopressin / Q000097:blood; D002302:Cardiac Output / Q000187:drug effects; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D015773:Enalaprilat / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007430:Intraoperative Care / Q000379:methods; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000503:physiopathology; D011184:Postoperative Period; D012079:Renal Circulation / Q000187:drug effects; D012083:Renin / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001127:Arginine Vasopressin; D012083:Renin; D015773:Enalaprilat